article thumbnail

AbbVie Cork facility €60 million expansion

European Pharmaceutical Review

Martin Shanahan, CEO of IDA Ireland declared: “It is a very significant day for a plant that already has a long and proud record of pharmaceutical manufacturing and innovation. Earlier this year, AbbVie was named Best Workplace for Women and ‘Biopharma Company of the Year’ at the latest Irish Pharma Industry Awards.

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

In particular, for the pharmaceutical industry, these talent shortages bring about a host of difficult challenges. This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Training and development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] The food sector has already initiated the publication of preliminary regulations aimed at restricting PFAS in packaging. [3].

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. ” Image from the Association of the British Pharmaceutical Industry (ABPI). Notable examples include a pair of 10-year alliances with mRNA specialists Moderna and BioNTech.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.